Pancreatic Cancer With Liver MetastasesPOligNCT07446946
Surgical Management of Pancreatic Cancer With Liver Metastasis (Oligometastasis)
An observational study of Pancreatic Cancer With Liver Metastases, run by Richard Hunger.
Trial summary
Pancreatic cancer is one of the most serious forms of cancer. When it has already spread to the liver, treatment usually consists of chemotherapy rather than surgery. However, in recent years, some hospitals have begun removing both the pancreatic tumor and liver metastases during the same operation in carefully… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer With Liver Metastases
- How many people
- 68,303 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2010to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Whole German Population
Who may be able to join
- C25 as primary diagnosis
- pancreatic resection (OPS:5-524, 5-525)
Who cannot join
- Missing data on age or sex
- transplantation procedures
- Patients with a total pancreatectomy following a partial pancreatic resection during the same hospitalization
About this study
Pancreatic cancer is one of the most serious forms of cancer. When it has already spread to the liver, treatment usually consists of chemotherapy rather than surgery. However, in recent years, some hospitals have begun removing both the pancreatic tumor and liver metastases during the same operation in carefully selected patients. This approach remains controversial, and it is unclear how often it is performed in everyday clinical practice and whether it is safe.
The aim of this study was to better understand current practice patterns in Germany and to evaluate the short-term safety of simultaneous pancreatic and liver surgery. Using nationwide hospital data, we examined all adult patients who underwent pancreatic resection for a malignant pancreatic tumor over a 14-year period.
Read more
The study was designed to test several key hypotheses. First, we hypothesized that simultaneous resection of pancreatic tumors and liver metastases is not an exceptional event but is already being performed in routine clinical care. Second, we examined whether adding liver surgery increases the risk of dying during the hospital stay compared to pancreatic surgery alone. Third, we investigated whether the extent of liver resection (minor versus major anatomical procedures) influences perioperative risk. Finally, we assessed whether hospital experience and surgical case volume affect patient safety in this complex setting.
Because the data were derived from a nationwide administrative registry, the study focuses on short-term outcomes during hospitalization. It does not address long-term survival or the overall oncologic benefit of combined surgery. Instead, the purpose of this analysis is to provide objective real-world data on how frequently this surgical strategy is used and whether it appears to be feasible from a perioperative safety perspective.
Read the detailed description
Study Design and Registry Framework This investigation represents a nationwide retrospective cohort study based on the German Diagnosis-Related Group (DRG) hospital discharge database covering the period 2010-2023. The DRG system constitutes a mandatory administrative registry capturing all inpatient hospitalizations across Germany, thereby providing full national coverage without center-level voluntary participation bias.
The registry includes patient demographics, ICD-10 diagnosis codes, OPS procedure codes, discharge status, and institutional identifiers. For this study, all adult patients (≥18 years) with a principal diagnosis coded as malignant neoplasm of the pancreas (ICD-10 C25) who underwent pancreatic resection were included.
Quality Assurance Plan The German DRG registry operates under a legally mandated standardized coding framework. Coding is performed by trained hospital coders and subject to institutional internal audits as well as external audits by health insurance funds and the Medical Service of Health Insurance (MD). Financial reimbursement is directly linked to coding accuracy, creating systematic incentives for data validity.
For this study:
Only validated national DRG datasets were used. Data were obtained from the Federal Statistical Office. All data were anonymized prior to analysis. Logical consistency checks were performed before statistical analysis. No site-level monitoring was required, as this is a population-based administrative dataset.
Data Validation and Registry Procedures
Data validation in the DRG system includes:
Automated plausibility checks at the hospital level. Cross-validation between diagnosis and procedure codes. Reimbursement-driven coding audits. Periodic national validation procedures.
Before analysis, additional study-specific validation steps were performed:
Removal of patients with missing age or sex. Hierarchical ranking of pancreatic procedures to avoid double counting. Exclusion of implausible combinations (e.g., total pancreatectomy following partial resection within same admission).
Verification of coding consistency between C78.7 (secondary liver malignancy) and liver resection codes.
Data Checks and Internal Consistency
Data were checked against predefined logical rules:
Age ≥18 years. Valid combinations of pancreatic resection types. Liver resection categorized as non-anatomic or anatomic based on OPS coding. Cross-check of metastatic liver diagnosis (C78.7) with liver resection procedures.
Range checks for continuous variables (e.g., age). Inconsistencies were excluded or corrected according to predefined rules.
Source Data Verification
As this is a nationwide administrative dataset, direct medical record review was not possible. However, source data integrity is supported by:
Mandatory hospital coding standards. Financial audit procedures. External audits by statutory health insurance authorities. National validation studies demonstrating reliability of DRG coding for major surgical procedures.
Therefore, indirect source data verification is inherent to the registry's structure, although patient-level chart verification was not performed.
Data Dictionary
Key variables included:
Demographics:
- Age (years)
- Sex (male/female)
Diagnoses:
- ICD-10 C25 (malignant neoplasm of pancreas)
- ICD-10 C78.7 (secondary malignant neoplasm of liver) Comorbidities defined via Charlson algorithm (Quan et al.)
Procedures: OPS codes for:
- Distal pancreatectomy
- Pancreatic head resection
- Total pancreatectomy
- Liver wedge resection
- Segmentectomy
- Hemihepatectomy
- Thermal ablation
Outcomes:
In-hospital mortality (binary) Failure to rescue (death after major complication) Institutional Variable
Annual hospital caseload categorized as:
<10, 10-19, 20-49, ≥50 pancreatic resections/year
Coding systems used:
ICD-10-GM (German modification) OPS (German procedure coding system) Charlson Comorbidity Index (Quan adaptation)
Data Management:
- Secure data storage.
- Anonymized dataset.
- Reproducible R scripts.
Analysis Workflow:
- Descriptive statistics.
- Group comparisons.
- Multivariable logistic regression.
- Volume-outcome marginal effect estimation.
Change Management Any analytic modification required documentation and version tracking in the statistical analysis script.
Sample Size Assessment
This study is based on complete nationwide capture (N = 68,303 resections). Given the large cohort size:
Statistical power was sufficient to detect small effect sizes. Mortality differences ≥1% were detectable with high precision. No formal prospective power calculation was required due to exhaustive national sampling.
The subgroup with simultaneous liver resection (n=2,447) provided adequate power for multivariable modeling.
Plan for Missing Data Administrative datasets typically have minimal missingness for key variables (age, sex, discharge status).
Approach:
Exclusion of patients with missing age or sex. No imputation performed. Comorbidity coding assumed absent if not coded. Logical inconsistencies were excluded prior to analysis. No multiple imputation was required.
Statistical Analysis Plan
Primary Objective:
Assess association between simultaneous liver resection and in-hospital mortality.
Secondary Objective:
Assess failure to rescue and volume-outcome relationships.
Analytical Principles
- Two-sided hypothesis testing.
- Significance threshold p < 0.05.
- Reporting of odds ratios with 95% confidence intervals.
Methods:
Descriptive analysis (means, medians, proportions). Chi-square and Wilcoxon tests. Multivariable logistic regression using Firth's correction to reduce small-sample bias.
Adjustment variables:
- Age group
- Sex
- Pancreatic procedure type
- Individual Charlson comorbidities
- Hospital case volume
- Year of operation
Subgroup analyses:
- Anatomic vs non-anatomic liver resection.
- Volume-stratified outcome modeling.
- Marginal standardized predicted probabilities for hospital volume categories.
All analyses were performed in R (version 4.3).
Limitations of Registry-Based Design No histopathological differentiation beyond ICD-10 C25. No systemic therapy data. No long-term survival. No 90-day mortality. No tumor burden quantification. Heterogeneous patient selection likely.
Summary This registry-based nationwide analysis applies structured validation procedures, predefined analytic rules, and standardized coding systems to evaluate the safety of simultaneous pancreatic and liver resections. While administrative data limit oncologic interpretation, the methodological framework ensures robust short-term safety assessment across a complete national cohort.
- Conditions
- Pancreatic Cancer With Liver Metastases
- Keywords
- Pancreatic cancer, liver metastases, oligometastatic disease, pancreatic resection, hepatectomy
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Pancreatic cancer with liver metastases | Primary diagnosis C25 and side diagnosis C78.7 | |
| Pancreatic cancer without liver metastases | Primary diagnosis C25 and without side diagnosis C78.7 |
What is being measured
The primary outcome is the main question the study is designed to answer.
30-Day in-hospital mortality
Postoperative death within 30 days after index surgery
Measured: 30 days
Failure-to-Rescue
Death after the occurrence of a major complication
Measured: Within 30 days after index surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2026
- Study start1 Jan 2010
- Primary completion31 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic Cancer With Liver MetastasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 68,303 participants (actual)
Sponsor and investigators
- Lead sponsor
- Richard Hunger
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Richard Hunger, Medizinische Hochschule Brandenburg Theodor Fontane
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07446946
- Sponsor's protocol ID
- POlig
- Acronym
- POlig
- Status last verified
- Feb 2026
- First submitted
- 26 Feb 2026
- Last updated
- 3 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The analyzed data is held by the Federal Statistical Office of Germany and the Statistical Offices of the Federal States. The data is not publicly available.
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surgical Management of Pancreatic Cancer With Liver Metastasis (Oligometastasis)
- ClinicalTrials.gov ID
- NCT07446946
- Acronym / sponsor ID
- POlig / POlig
- Conditions
- Pancreatic Cancer With Liver Metastases
- Keywords
- Pancreatic cancer, liver metastases, oligometastatic disease, pancreatic resection, hepatectomy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 68,303 participants (actual)
- Lead sponsor
- Richard HungerUniversity, hospital or other
- Study start
- 1 Jan 2010 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 3 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pancreatic cancer is one of the most serious forms of cancer. When it has already spread to the liver, treatment usually consists of chemotherapy rather than surgery. However, in recent years, some hospitals have begun removing both the pancreatic tumor and liver metastases during the same operation in carefully selected patients. This approach remains controversial, and it is unclear how often it is performed in everyday clinical practice and whether it is safe.
The aim of this study was to better understand current practice patterns in Germany and to evaluate the short-term safety of simultaneous pancreatic and liver surgery. Using nationwide hospital data, we examined all adult patients who underwent pancreatic resection for a malignant pancreatic tumor over a 14-year period.
The study was designed to test several key hypotheses. First, we hypothesized that simultaneous resection of pancreatic tumors and liver metastases is not an exceptional event but is already being performed in routine clinical care. Second, we examined whether adding liver surgery increases the risk of dying during the hospital stay compared to pancreatic surgery alone. Third, we investigated whether the extent of liver resection (minor versus major anatomical procedures) influences perioperative risk. Finally, we assessed whether hospital experience and surgical case volume affect patient safety in this complex setting.
Because the data were derived from a nationwide administrative registry, the study focuses on short-term outcomes during hospitalization. It does not address long-term survival or the overall oncologic benefit of combined surgery. Instead, the purpose of this analysis is to provide objective real-world data on how frequently this surgical strategy is used and whether it appears to be feasible from a perioperative safety perspective.
Detailed description
Study Design and Registry Framework This investigation represents a nationwide retrospective cohort study based on the German Diagnosis-Related Group (DRG) hospital discharge database covering the period 2010-2023. The DRG system constitutes a mandatory administrative registry capturing all inpatient hospitalizations across Germany, thereby providing full national coverage without center-level voluntary participation bias.
The registry includes patient demographics, ICD-10 diagnosis codes, OPS procedure codes, discharge status, and institutional identifiers. For this study, all adult patients (≥18 years) with a principal diagnosis coded as malignant neoplasm of the pancreas (ICD-10 C25) who underwent pancreatic resection were included.
Quality Assurance Plan The German DRG registry operates under a legally mandated standardized coding framework. Coding is performed by trained hospital coders and subject to institutional internal audits as well as external audits by health insurance funds and the Medical Service of Health Insurance (MD). Financial reimbursement is directly linked to coding accuracy, creating systematic incentives for data validity.
For this study:
Only validated national DRG datasets were used. Data were obtained from the Federal Statistical Office. All data were anonymized prior to analysis. Logical consistency checks were performed before statistical analysis. No site-level monitoring was required, as this is a population-based administrative dataset.
Data Validation and Registry Procedures
Data validation in the DRG system includes:
Automated plausibility checks at the hospital level. Cross-validation between diagnosis and procedure codes. Reimbursement-driven coding audits. Periodic national validation procedures.
Before analysis, additional study-specific validation steps were performed:
Removal of patients with missing age or sex. Hierarchical ranking of pancreatic procedures to avoid double counting. Exclusion of implausible combinations (e.g., total pancreatectomy following partial resection within same admission).
Verification of coding consistency between C78.7 (secondary liver malignancy) and liver resection codes.
Data Checks and Internal Consistency
Data were checked against predefined logical rules:
Age ≥18 years. Valid combinations of pancreatic resection types. Liver resection categorized as non-anatomic or anatomic based on OPS coding. Cross-check of metastatic liver diagnosis (C78.7) with liver resection procedures.
Range checks for continuous variables (e.g., age). Inconsistencies were excluded or corrected according to predefined rules.
Source Data Verification
As this is a nationwide administrative dataset, direct medical record review was not possible. However, source data integrity is supported by:
Mandatory hospital coding standards. Financial audit procedures. External audits by statutory health insurance authorities. National validation studies demonstrating reliability of DRG coding for major surgical procedures.
Therefore, indirect source data verification is inherent to the registry's structure, although patient-level chart verification was not performed.
Data Dictionary
Key variables included:
Demographics:
- Age (years)
- Sex (male/female)
Diagnoses:
- ICD-10 C25 (malignant neoplasm of pancreas)
- ICD-10 C78.7 (secondary malignant neoplasm of liver) Comorbidities defined via Charlson algorithm (Quan et al.)
Procedures: OPS codes for:
- Distal pancreatectomy
- Pancreatic head resection
- Total pancreatectomy
- Liver wedge resection
- Segmentectomy
- Hemihepatectomy
- Thermal ablation
Outcomes:
In-hospital mortality (binary) Failure to rescue (death after major complication) Institutional Variable
Annual hospital caseload categorized as:
<10, 10-19, 20-49, ≥50 pancreatic resections/year
Coding systems used:
ICD-10-GM (German modification) OPS (German procedure coding system) Charlson Comorbidity Index (Quan adaptation)
Data Management:
- Secure data storage.
- Anonymized dataset.
- Reproducible R scripts.
Analysis Workflow:
- Descriptive statistics.
- Group comparisons.
- Multivariable logistic regression.
- Volume-outcome marginal effect estimation.
Change Management Any analytic modification required documentation and version tracking in the statistical analysis script.
Sample Size Assessment
This study is based on complete nationwide capture (N = 68,303 resections). Given the large cohort size:
Statistical power was sufficient to detect small effect sizes. Mortality differences ≥1% were detectable with high precision. No formal prospective power calculation was required due to exhaustive national sampling.
The subgroup with simultaneous liver resection (n=2,447) provided adequate power for multivariable modeling.
Plan for Missing Data Administrative datasets typically have minimal missingness for key variables (age, sex, discharge status).
Approach:
Exclusion of patients with missing age or sex. No imputation performed. Comorbidity coding assumed absent if not coded. Logical inconsistencies were excluded prior to analysis. No multiple imputation was required.
Statistical Analysis Plan
Primary Objective:
Assess association between simultaneous liver resection and in-hospital mortality.
Secondary Objective:
Assess failure to rescue and volume-outcome relationships.
Analytical Principles
- Two-sided hypothesis testing.
- Significance threshold p < 0.05.
- Reporting of odds ratios with 95% confidence intervals.
Methods:
Descriptive analysis (means, medians, proportions). Chi-square and Wilcoxon tests. Multivariable logistic regression using Firth's correction to reduce small-sample bias.
Adjustment variables:
- Age group
- Sex
- Pancreatic procedure type
- Individual Charlson comorbidities
- Hospital case volume
- Year of operation
Subgroup analyses:
- Anatomic vs non-anatomic liver resection.
- Volume-stratified outcome modeling.
- Marginal standardized predicted probabilities for hospital volume categories.
All analyses were performed in R (version 4.3).
Limitations of Registry-Based Design No histopathological differentiation beyond ICD-10 C25. No systemic therapy data. No long-term survival. No 90-day mortality. No tumor burden quantification. Heterogeneous patient selection likely.
Summary This registry-based nationwide analysis applies structured validation procedures, predefined analytic rules, and standardized coding systems to evaluate the safety of simultaneous pancreatic and liver resections. While administrative data limit oncologic interpretation, the methodological framework ensures robust short-term safety assessment across a complete national cohort.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pancreatic cancer with liver metastases | – | –Primary diagnosis C25 and side diagnosis C78.7 |
| Pancreatic cancer without liver metastases | – | –Primary diagnosis C25 and without side diagnosis C78.7 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Whole German Population
Key inclusion criteria (2 listed)
- C25 as primary diagnosis
- pancreatic resection (OPS:5-524, 5-525)
Key exclusion criteria (3 listed)
- Missing data on age or sex
- transplantation procedures
- Patients with a total pancreatectomy following a partial pancreatic resection during the same hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
30-Day in-hospital mortality
Time frame: 30 days
Postoperative death within 30 days after index surgery
Failure-to-Rescue
Time frame: Within 30 days after index surgery
Death after the occurrence of a major complication
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2026.
- Individual participant dataSharing planned: No. The analyzed data is held by the Federal Statistical Office of Germany and the Statistical Offices of the Federal States. The data is not publicly available.
Related trials for Pancreatic Cancer With Liver Metastases
Recruiting
CREO - Microwave Ablation Feasibility Study
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic)
RecruitingPhase 1
A Study of MGC026 in Participants With Advanced Solid Tumors
Advanced Solid Tumor, Advanced Cancer
Not yet recruitingPhase 2
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
Liver Metastases, Non-Small Cell Lung Cancer
RecruitingObservational study
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma
Active, not recruiting
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Breast Cancer, Colon Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer With Liver Metastases, run by Richard Hunger.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
30-Day in-hospital mortality (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026.